Compare NXGL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXGL | SILO |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.1M |
| IPO Year | 2019 | 2011 |
| Metric | NXGL | SILO |
|---|---|---|
| Price | $0.17 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 281.0K | 46.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.00 | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,421,000.00 | $72,102.00 |
| Revenue This Year | $38.23 | N/A |
| Revenue Next Year | $53.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.16 | $0.22 |
| 52 Week High | $2.89 | $7.95 |
| Indicator | NXGL | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 27.36 | 18.64 |
| Support Level | $0.16 | $0.30 |
| Resistance Level | $0.59 | $4.80 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 13.77 | 20.11 |
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.